Table 2.
Candidate genes of the dopamine pathway, showing significantly increased methylation (p < 0.01 ) following olanzapine treatment in hippocampus, cerebellum and liver, in a rat model in vivo
| Gene name | Accession | Chr. | Strand | TSS | TTS | EH-CH | EC-CC | EL-CL |
|---|---|---|---|---|---|---|---|---|
| Drd5 | NM_012768 | chr14 | - | 77769487 | 77768059 | 1 | 1 | 1 |
| Camkk2 | NM_031338 | chr12 | + | 34772493 | 34938479 | 1 | 1 | |
| Calm3 | NM_012518 | chr1 | - | 77252717 | 77245608 | 1 | ||
| Kcnj2 | NM_017296 | chr10 | + | 100574984 | 100576268 | 1 | ||
| Kcnj4 | NM_053870 | chr7 | - | 117603827 | 117601722 | 1 | ||
| Cacna1c | NM_012517 | chr4 | - | 155517389 | 154895690 | 1 | ||
| Ppp3ca | NM_017041 | chr2 | + | 234130175 | 234409232 | 1 | 1 | |
| Adcy3 | NM_130779 | chr6 | + | 27118324 | 27202275 | 1 | ||
| Plcd1 | NM_017035 | chr8 | - | 124052193 | 124023089 | 1 | ||
| Ppp2r2d | NM_144746 | chr1 | + | 198640770 | 198674758 | 1 | ||
| Ppp1r1b | NM_138521 | chr10 | + | 87121888 | 87131587 | 1 | ||
| Nos1 | NM_052799 | chr12 | - | 39869484 | 39811720 | 1 | ||
| Itpr1 | NM_001007235 | chr4 | + | 143705359 | 144030051 | 1 | ||
| Ppp1r14b | NM_172045 | chr1 | + | 209648656 | 209650767 | 1 | ||
| Crem | NM_001110860 | chr17 | + | 62770632 | 62837670 | 1 | ||
| Slc18a2 | NM_013031 | chr1 | + | 265789916 | 265824551 | 1 | ||
| Ddc8 | NM_001017481 | chr10 | - | 108349394 | 108336343 | 1 | ||
| Drd2 | NM_012547 | chr8 | + | 52641159 | 52707749 | 1 | ||
| Drd1a | NM_012546 | chr17 | + | 16655925 | 16658161 | 1 |
Chr chromosome, TSS transcription start site, TTS transcription termination site, EH-CH, EC-CC, EL-CL the number of differentially enriched peaks that showed increased in methylation in Olanzapine treated experimental (E) rats as compared to matched-controls (C) in hippocampus (H), cerebellum (C) and liver (L), respectively.